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Abstract
Background: Patients with congenital choledochal cyst are at risk of the development of hepatobiliary
malignancy, with recommended treatment of choledochal cyst being surgical excision. The development
of cholangiocarcinoma more than 10 years after excision of choledochal cysts is rare, with less than 21 cases
reported in the literature from 1972 to 2014. This is the first reported case of metachronous recurrence after
a previously excised adenocarcinoma within a choledochal cyst.
Case presentation: Herein, we review the case of a patient with cholangiocarcinoma arising 13 years post
excision of a Todani type 1 choledochal cyst and discuss the theories of carcinogenesis and long-term
management of patients with choledochal cysts. The long-term development of a malignancy must be
considered in these patients.
Conclusions: Reviewing all published cases to date, regular follow-up post resection did not improve on the
resectability and long-term survival of these patients. Patients presenting with symptoms did not prejudice
against resectability. Despite curative resection, median survival was dismal. Optimal long-term follow-up
strategies for these patients remain to be elucidated.
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Background
There is a significant association between congenital
choledochal cysts and the development of hepatobili-
ary malignancies, with an incidence ranging between
2.5 and 28 % [1, 2].
The complete surgical excision of the choledochal
cyst with biliary enteric anastomosis is indicated as
this reduces the risk of cholangiocarcinoma to
between 0.7 and 5.4 % [3]. The time interval and risk
factors for the development of cancer post resection
are poorly understood, with only several case reports
and small case series published to date.
We report a rare case of a cholangiocarcinoma arising
13 years post excision of a Todani type 1 choledochal
cyst and discuss the process of carcinogenesis and the
merits of follow-up in these patients.
Case presentation
A 59-year-old Chinese lady has been on follow-up
with our institution for a previous Todani type 1
choledochal cyst for which she underwent cyst exci-
sion with Roux-en-Y hepaticojejunostomy in 2001.
Subsequent pathology revealed the cyst containing an
incidental focus of adenocarcinoma with clear margins
of resection (Fig. 1).
Since resection, she had been regularly reviewed with
computed tomography (CT) scans of the abdomen and
CA 19-9 levels performed annually. A CA 19-9 level
performed in 2012 showed a slightly elevated level of
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52 IU/ml. Magnetic resonance imaging (MRI) of the
liver was subsequently performed in October 2012 did
not show any evidence of recurrence. An interval CT
abdomen performed in December 2013 (Fig. 2) was
similarly unremarkable, and she was given a subsequent
appointment for a repeat CA 19-9 and imaging in a
years’ time.
She represented early for clinic review in October
2014 complaining of intermittent fevers for several
months. These resolved with short courses of anti-
biotic therapy prescribed by her local general practi-
tioner. During this period, there was a slight elevation
of transaminases and the CA 19-9 level rose to
487 IU/ml. A magnetic resonance cholangiopancreato-
graphy (MRCP) was performed which showed a
central large heterogenous mass encasing the main
portal vein and biliary ductal confluence suggestive of
cholangiocarcinoma (Fig. 3). There was also an inde-
terminate filling defect in the right intrahepatic duct
and loss of signal in the middle and left hepatic veins.
An endoscopic ultrasound-guided biopsy of the mass
confirmed the finding of moderately differentiated
adenocarcinoma consistent with cholangiocarcinoma
(Fig. 4). A percutaneous trans-hepatic cholangiog-
raphy and biliary drainage was subsequently per-
formed for worsening biliary obstruction. Bile culture
was positive for E. coli spp., and amylase levels were
normal.
This patient was discussed at the multidisciplinary
tumour board, and decision was made for palliative
chemotherapy for locally advanced unresectable disease.
The patient received 3 cycles of gemcitabine 1300 mg
and cisplatin 35 mg. However, this was complicated by
recurrent cholangitis and sepsis leading to early cessa-
tion of chemotherapy. This eventually led to progressive
disease, and the patient passed away 10 months post
diagnosis of her recurrence.
Conclusions
Cholangiocarcinoma is the second most common pri-
mary liver cancer after hepatocellular carcinoma and
accounts for approximately 10–25 % of all hepatobiliary
malignancies [4]. Risk factors for the development of
cholangiocarcinoma include parasitic infections, primary
sclerosing cholangitis, choledochal cysts, hepatolithiasis,
and toxins [5]. The development of cholangiocarci-
noma can also occur after biliary enteric anastomoses.
Tocchi et al. reported a rate of 5.5 %, where 55 out
of 1000 cases developed cholangiocarcinoma after bil-
iary enteric anastomoses for benign pathologies [6].
There have been 31 cases (Table 1) of cholangiocar-
cinoma occurring after resection of choledochal cyst
reported in the literature between 1972 and 2014 with
the median time to recurrence being 6 years (range
2–34 years). The most common type of choledochal
cysts in these patients was Todani type 4a. Our
patient had a recurrence 13 years post resection of a
Todani type 1 cyst. In addition, our patient had an
incidental focus of adenocarcinoma in the initial cyst.
This is the first reported case of metachronous
recurrence after a previously excised adenocarcinoma
within a choledochal cyst [7–24]. Moertel first pro-
posed a definition for synchronous cancers as those
occurring within 6 months of the first primary cancer
and for metachronous cancers, as those occurring
more than 6 months later. While synchronous gall-
bladder and biliary tree cancers have been reported
between 5 and 7.4 % of cases, occurrence of meta-
chronous cancers has been rarely reported for extra-
hepatic bile duct cancers [25].
Anomalous union of pancreaticobiliary ductal (AUPBD)
junction without congenital choledochal cyst is a risk
factor for hepatobiliary malignancies and is defined as
the abnormal junction of the pancreatic duct and
common bile duct that occurs outside the duodenal
wall to form a long common channel (>15 mm).
Kimura et al. has proposed a classification system for
AUPBD where type 1 is defined as the pancreatic duct
joined to the common bile duct (as the main duct) and
type 2 is defined as the common bile duct joined to the
pancreatic duct (as the main duct) [26]. The anomalous
junction is also often associated with a choledochal cyst
or a biliary tract carcinoma which may be due to the re-
flux of activated pancreatic fluid; type 1 abnormalities
Choledochal cyst H&E x 4
Choledochal cyst H&E x10
a
b
Fig. 1 a Partly denuded cyst lining with stretches of high-grade
dysplasia and invasive tumour at the upper edge; see Fig. 2b for
×10 view of area. b Invasive adenocarcinoma featuring both
invasive irregular glands and solid tumour with clear cytoplasm
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carry a higher risk of biliary tract and gallbladder
malignancies [27].
Various theories have been put forward to explain the
development of malignancy in these patients with pre-
viously resected choledochal cysts. Firstly, some authors
have suggested that the epithelium of the remnant bile
duct wall is already at a precancerous stage at the time
of surgery and hence, the development of cholangio-
carcinoma is merely a result of carcinogenesis during
the postoperative period [7]. Secondly, the existence of
stenosis at the anastomosis or in the intrahepatic bile
duct may induce carcinogenesis. Moreover, some have
postulated that carcinogenesis is caused by repeated
damage of the biliary epithelium by bile fluid as well
as bacterial contamination which leads to mucosal
metaplasia [8]. Lastly, cholangiocarcinoma can develop
spontaneously in the general population which may
explain the largely variable intervals of presentation of
cholangiocarcinoma in these patients.
Kumamoto et al. have postulated that the reflux of
activated pancreatic juice is the strongest contributing
factor to carcinogenesis. A study of biliary enteric
reconstruction performed for benign disease has shown
that the incidence of cholangiocarcinoma after choledo-
choduodenostomy is higher compared to hepaticojeju-
nostomy (7.6 vs. 1.9 %) [6]. They postulate that this
significant difference in incidence rate occurs because
activated pancreatic juice can more easily flow back to
the biliary tract in a choledochoduodenostomy as
compared to a hepaticojejunostomy and hence, the
reflux of activated pancreatic juice might be the stron-
gest carcinogenic factor. However, of the cases reported
in the literature, few patients had reconstruction with a









Fig. 2 a Coronal view of the CT abdomen showing no recurrence of tumour. b Transverse views of the CT abdomen showing no
recurrence of tumour
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benign pathologies, in patients with previous choledo-
chal cysts, reflux of pancreatic juice may not be the
strongest carcinogenic factor.
Other studies have suggested that the epithelium of
the remnant bile duct wall is already at a precancerous
stage at the time of surgery and hence, development
of cholangiocarcinoma is merely a result of carcino-
genesis during the postoperative period. This is seen
mostly in Todani type 4a cysts where development of
cholangiocarcinoma mainly occurs in the dilated intra-
hepatic bile duct [9]. Our patient developed cholangio-
carcinoma after excision of a type 1 cyst, suggesting
that despite the initial cyst only involving extra-hepatic
ducts, the entire biliary tree despite being of normal
calibre may have a high risk of field cancerization.
While the risk of interval malignancy is well de-
scribed, there are no guidelines for the duration of
follow-up and the type of investigations that patients
should undergo after initial surgery for choledochal
cyst. In the 18 case reports in the literature, 17 pa-
tients were not followed up routinely with radiological
imaging and tumour markers as compared to our pa-
tient who was followed up yearly with CT scans and
CA 19-9 levels. Twelve of these patients had no long-
term follow-up. Only one patient had regular hepato-
biliary system (HBS) ultrasound, tumour markers and
liver function test (LFT) in view of her hepatitis C
status. In all 17 patients without routine imaging or
tumour marker follow-up post excision of choledochal
cyst, cholangiocarcinoma was detected only when
these patients were symptomatic with cholangitis at
presentation. In the one patient with regular follow-
up, development of cholangiocarcinoma was detected
based on ultrasound HBS.
Nishayama et al. has suggested lifelong biannual
follow-up with CT scans and CA 19-9 levels in patients
with high risk of development of cholangiocarcinoma
and annual ultrasounds in patients with low risk [10].
High-risk features include the presence of dilated
biliary ducts post resection and reconstruction with
choledochoduodenostomy and hepatitis. The rationale
behind such stringent follow-up is that resection would
be more difficult or even not be possible in patients
with more advanced disease. The belief is that with
tighter follow-ups, development of cholangiocarci-
noma can be picked up at an early stage, giving these
patients a greater chance of cure [8].
Including our patient, 21 out of 32 patients had de-
velopment of cholangiocarcinoma more than 10 years
post excision of choledochal cyst (Table 2). Of these 20
patients, 12 underwent curative resection (60 %). How-
ever, 11 patients had no long-term follow-up and recur-
rences were detected due to the patients’ symptoms.
This is in comparison with 5 out of 11 patients with
development of cholangiocarcinoma less than 10 years
post excision of choledochal cyst that underwent
curative resection of cholangiocarcinoma (45 %). Of
these five patients, four patients (80 %) were followed
up regularly with clinic reviews till recurrence of
cholangiocarcinoma. This suggests that perhaps follow-
up with regular clinic reviews alone does not affect
resectability of cholangiocarcinoma. Also, detection of
cholangiocarcinoma based on the patient’s symptoms
does not inevitably result in unresectable disease.
The follow-up of such patients with radiological
imaging and blood investigations over their lifetime would
expose patients to repeated procedures. This may have
Fig. 4 Endoscopic ultrasound-guided biopsy of the mass showing
findings of moderately differentiated adenocarcinoma consistent
with cholangiocarcinoma
Fig. 3 MRI liver showing a central large heterogenous mass inseparable
and encasing the main portal vein and biliary ductal confluence
suggestive of cholangiocarcinoma
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been useful to detect recurrences that occur <10 years
post resection with 80 % of recurrence detected on follow-
up. For detection beyond 10 years post resection, the
optimum strategy for follow-up is uncertain. This was
seen in our patient where even though tumour markers
and imaging were performed annually, the disease was still
advanced and unresectable at presentation.
More importantly, this study demonstrates that there
is a significant long-term risk of cholangiocarcinoma
recurring even after 10 years. These patients should be
offered long term regular follow-up with a combination
of clinical evaluation, radiological imaging and tumour
markers.
In addition, in terms of overall survival, the literature
shows overall survival rates after resection of cholan-
giocarcinoma in these patients to be 50 % at 2 years
posttreatment and 25 % at 3 years posttreatment, with
a median survival time of 15 months, with no 4-year
survivors [11]. This suggests that despite being able to
perform curative resection, biliary malignancy shows an
unfavourable outcome reflecting a more aggressive
biology then de novo cholangiocarcinoma.
In conclusion, this is a case of intrahepatic cholangiocar-
cinoma arising 13 years after excision of a choledochal
cyst. We assessed the theories of carcinogenesis and
postulated that the cancer development was related to the
reflux of intestinal bacteria into the bile duct. While long-
term follow-up should not be discouraged, the available
literature suggest that the best strategy remains to be
defined due to the variability in the duration of the repre-
sentation, the advanced disease of representation, and the
poor prognosis.
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Table 2 Characteristics of patients (including current study)
Resected Unresectable
Cholangiocarcinoma development more
than 10 years post excision (n = 21)
12 9
Cholangiocarcinoma development less
than 10 years post excision (n = 11)
5 6



















18 39 (18–62) 14 type 4a, 2
type 1, 2 ND
















4 41 (27–65) 2 type 1,
2 type 4a
19 (13–32) 181 (7–484) 2 intrahepatic
duct, 1 hilar, 1
intrapancreatic
duct
All resected 15 (9–43)
Rossi et al.
1986 [16]









1 ND 4 a 2 24 Intrahepatic Resected 24
Joseph et al.
1996 [23]
1 29 4 a 3 NDa Intrahepatic Unresectable 36
Shah et al.
2009 [24]
1 42 4 a 2 28 Extra-hepatic
bile duct
Unresectable 2
ND not documented, CC cholangiocarcinoma
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